Clinical Trials for Mesothelioma Patients: Bortezomib and Cisplatin

Read about a current clinical trial being conducted to study the effects of Bortezomib and Cisplatin for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. This study is being conducted ONLY in the United Kingdom.

Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

Official Title: Phase II Study of Bortezomib (VELCADE) With Cisplatin as First Line Treatment of Malignant Mesothelioma

Rationale: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as Cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving Bortezomib together with Cisplatin may kill more tumor cells.

Requisite Conditions: Malignant Mesothelioma

Outline: This is a nonrandomized, open-label, multicenter study. Patients receive Cisplatin IV over 1 hour on day 1 and Bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed every 3 months.

Intervention:

Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney